319 related articles for article (PubMed ID: 26572150)
1. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
2. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
3. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
4. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
5. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
6. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
7. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
9. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
10. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
11. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance.
Wang F; Liu R; Lee SW; Sloss CM; Couget J; Cusack JC
Oncogene; 2007 Mar; 26(14):2006-16. PubMed ID: 17001310
[TBL] [Abstract][Full Text] [Related]
12. Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam SO; Odawara T; Manabe S; Ishikawa T; Itamochi H; Kigawa J; Takada S; Asahara H; Kuroki M; Miyamoto S
Cancer Med; 2014 Oct; 3(5):1159-69. PubMed ID: 25060396
[TBL] [Abstract][Full Text] [Related]
13. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
16. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
17. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant.
Rivetti S; Lauriola M; Voltattorni M; Bianchini M; Martini D; Ceccarelli C; Palmieri A; Mattei G; Franchi M; Ugolini G; Rosati G; Montroni I; Taffurelli M; Solmi R
Int J Immunopathol Pharmacol; 2011; 24(3):639-49. PubMed ID: 21978696
[TBL] [Abstract][Full Text] [Related]
19. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
Yagi H; Yotsumoto F; Miyamoto S
Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
